AstraZeneca sees stock market value slump by more than £20bn after drug setback - The FTSE 100 firm found the Wainua drug ...
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
AstraZeneca loses £20 billion in value after disappointing trial results for a key heart disease drug. Find out more.
By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...
Heavy falls in AstraZeneca saw London’s FTSE 100 underperform European peers, while investors continue to weigh up ...
Astra's shares tumbled 10.5% after it said its Wainua drug - which it is developing with Ionis - failed to reduce deaths ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results